Slide 35: I think they are probably looking at their accessible patients globally (~12m in Aus, ~180m in US) and then saying that number is not likely to get much bigger (population growth slow), but the digitally accessible patients are expected to grow (from ~2m in Aus, 5-10m in US).
What is quite damning is:
- Australian revenues of ~10m in FY21
- Australian OPEX of ~19m in FY21
=> this business just sucks IMO.....$159-179 per month per pharmacy makes no sense if they are saying each patient on medadvisor adds ~$200 pa in revenue per pharmacy (with pharmacy margins, that is probably 20-30 patients on the app per year!). The question is, why would you expand into the UK on a loss making business.....the model is not working if the subscription fees are not enough and the pharma companies are not paying for patient programs in Aus.
US is going to make/break the case IMO
Add to My Watchlist
What is My Watchlist?
